From August 29 to September 1, Madrid hosts the European Society of Cardiology Congress (ESC Congress) and the World Heart Federation World Congress of Cardiology
REBOOT trial, coordinated by the CNIC, shows that treatment with beta-blockers provides no benefit to patients who experience an uncomplicated heart attack that leaves the contractile function of the heart intact.
The study, published in JACC: CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves mitochondrial function, improves myocardial energetics, and prevents degenerative changes in heart structure
The findings of this study have been key for the development of REACT, a new research project, that will count on the collaboration of Santander Bank, and will expand the study of the age group for the prevention of cardiovascular diseases, which will include 8,000 new participants.
